

Cover Story
Free
By Matthew Bin Han Ong
Joyce Shoffner would never have predicted that Duke University, an institution she revered and at one time worked for, would put her in a breast cancer clinical trial testing a fraudulent technology.
In Brief
Drugs & Targets
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Did peer review fail? Nature Medicine’s chronotherapy paper retraction raises questions
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- The future of oncology: Early-career scientists need mentorship and a new academic model
- The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long” - Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42












